Home / Precision Medicine (page 29)

Precision Medicine

Merck Serono Partners with Illumina to Develop a University NGS-Based Oncology Diagnostic

Illumina announced that it is partnering with Merck Serono to develop a universal oncology diagnostic that uses next-generation sequencing (NGS). The companies will collaborate to develop a universal NGS-based oncology diagnostic for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine. The …

Read More »

Quest Diagnostics Announces Availability of Exclusive Whole Exome Sequencing Service for Diagnosis of Pediatric Neurological Disorders

Quest Diagnostics announced that it is now offering a whole exome sequencing service aimed to enhance the diagnosis of rare neurological disorders in pediatric population. The leading provider of diagnostic information services today announced the availability of Neurome, a whole exome sequencing service. Leading genomics-based diagnostic laboratory, Personalis, Inc. developed …

Read More »

Novartis Sells its RNAi Assets to Arrowhead Research

Today, Arrowhead Research Corporation announced that it has acquired Novartis’ entire RNAi business for $10 million in cash and $25 million in stock. The deal gives Arrowhead Novartis’ complete RNAi research and development portfolio and associated assets, including assignment of certain Novartis patents and patent applications related to RNAi therapeutics, …

Read More »

Gene Mutation May Predict Immunotherapy Outcome in Melanoma Patients

Melanoma patients whose tumors had a specific gene mutation demonstrated better response and treatment outcomes when treated with immunotherapies, according to a new study. Researchers found that among melanoma patients who were treated with immunotherapies, individuals whose tumors had mutations in the NRAS gene responded better to treatment compared to …

Read More »

Bristol-Myers Squibb Signs a Prostate Cancer Vaccine Deal with Bavarian Nordic

Bristol-Myers Squibb Co. (BMS) said that it has entered into a $1 billion deal with Danish biotechnology company Bavarian Nordic for rights to a late-stage prostate cancer vaccine. The companies entered into an agreement that provides BMS an exclusive option to license and commercialize Prostvac, Bavarian Nordic’s investigational Phase III …

Read More »

Blueprint Medicines and Alexion Partner for Drugs Targeting a Rare Genetic Disease

Rare disease maker Alexion Pharmaceuticals has partnered with Blueprint Medicines to develop drugs for a rare genetic disease. Blueprint Medicines said that the companies have formed a strategic collaboration to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which causes a rare genetic disease. Blueprint …

Read More »

Intermountain Cancer Genomics Uses DNAnexus Technology to Bring Precision Medicine to Patients

DNAnexus Inc., a pioneer in cloud-based genome informatics and data management, recently announced that Intermountain Cancer Genomics is now utilizing its technology platform for the center’s personalized treatment options for cancer patients. The DNAnexus platform allows Intermountain Cancer Genomics to run its bioinformatics pipeline in the cloud, providing unmatched computational …

Read More »

Four New Centers Join World’s Largest Precision Cancer Research Network

The Oncology Research Information Exchange Network (ORIEN), founded by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCC-James), announced that it has expanded with the addition of four nationally recognized cancer centers. ORIEN, a research …

Read More »

Foundation Medicine and H3 Biomedicine Partner for Precision Medicine in Cancer

Today, Foundation Medicine, Inc. and H3 Biomedicine Inc. announced that they will collaborate to develop precision therapies for cancer. The companies said that they have entered a multi-year collaboration for the discovery and development of precision medicines in oncology, utilizing Foundation Medicine’s comprehensive genomic knowledgebase of more than 35,000 genomic …

Read More »